PHR1499
氟比洛芬
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
氟比洛芬, (±)-2-氟-α-甲基-4-联苯基乙酸, L-790,330
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
C6H5C6H3(F)CH(CH3)CO2H
化学文摘社编号:
分子量:
244.26
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
225-827-6
MDL number:
产品名称
氟比洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
InChI key
SYTBZMRGLBWNTM-UHFFFAOYSA-N
InChI
1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
SMILES string
CC(C(O)=O)c1ccc(c(F)c1)-c2ccccc2
grade
certified reference material
pharmaceutical secondary standard
agency
traceable to Ph. Eur. F0285200
traceable to USP 1285750
API family
flurbiprofen
CofA
current certificate can be downloaded
packaging
pkg of 500 mg
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
mp
110-112 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
Quality Level
Gene Information
human ... PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Other Notes
To see an example of a Certificate of Analysis for this material enter LRAA3047 in the slot below. This is an example certificate only and may not be the lot that you receive.
Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Biochem/physiol Actions
环氧合酶 (COX) 抑制剂；具有抗真菌活性的非甾体抗炎剂。S 对映体可抑制前列腺素的合成，同时具有消炎和镇痛活性，而 R 对映体不会抑制前列腺素的合成，只表现出镇痛活性。
Fluibiprofen is a cyclooxygenase (COX) inhibitor, which is an enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This decreases the prostaglandins which cause inflammation, pain, swelling and fever. Flurbiprofen inhibits the activity of both COX-1 and -2. The S enantiomer inhibits prostaglandin synthesis and has both anti-inflammatory and analgesic activity, while the R enantiomer does not inhibit prostaglandin synthesis and displays only analgesic activity.
Analysis Note
These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.
Application
Flurbiprofen may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and biological samples by various analytical techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Flurbiprofen is a non-selective, non-steroidal anti-inflammatory drug (NSAID) that is widely used against rheumatoid arthritis. It is also effective against vernal keratoconjunctivitis, post-operative ocular inflammation, herpetic stromal keratitis, excimer laser photorefractive keratectomy and ocular gingivitis.
Flurbiprofen is a non-selective, non-steroidal anti-inflammatory drug (NSAID) that is widely used against rheumatoid arthritis. It is also effective against vernal keratoconjunctivitis, post-operative ocular inflammation, herpetic stromal keratitis, excimer laser photorefractive keratectomy and ocular gingivitis.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
The determination of non-steroidal antiinflammatory drugs in pharmaceuticals by capillary zone electrophoresis and micellar electrokinetic capillary chromatography.
Donato MG, et al.
Journal of Pharmaceutical and Biomedical Analysis, 12(1), 21-26 (1994)
Simultaneous Determination of Ceftriaxone Sodium and Non Steroidal Anti?Inflammatory Drugs in Pharmaceutical Formulations and Human Serum by RP?HPLC.
Sultana N, et al.
J. Chin. Chem. Soc., 57(6), 1278-1285 (2010)
Determination of flurbiprofen in pharmaceutical formulations by UV spectrophotometry and liquid chromatography.
Sajeev C, et al.
Analytica Chimica Acta, 463(2), 207-217 (2002)
Sample pretreatment and determination of non steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by HPLC-UV-MS and μ-HPLC.
Mohamed S, et al.
Current Medicinal Chemistry, 12(5), 573-588 (2005)
Francesco Cilurzo et al.
Drug development and industrial pharmacy, 41(2), 183-189 (2013-10-30)
Abstract This work aims to establish if the assays recently introduced by EMA (Guideline on quality of transdermal patches-draft) and USP (Specific tests for transdermal delivery systems) to characterize transdermal patches (TP) are suitable for medicated plasters (MP). Six approved
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持